CSPC Pharmaceutical Publishes Updated Phase III OS Results for Anbenitamab
CSPC Pharmaceutical published updated Phase III overall-survival results for anbenitamab in HER2-positive advanced gastric cancer.
CSPC Pharmaceutical published updated Phase III overall-survival results for anbenitamab in HER2-positive advanced gastric cancer.